Salveen Richter
Stock Analyst at Goldman Sachs
(2.99)
# 1,431
Out of 4,918 analysts
191
Total ratings
42.86%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Salveen Richter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $29 | $15.91 | +82.28% | 5 | Jun 17, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $37 | $18.86 | +96.18% | 1 | Jun 16, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $51 → $44 | $6.42 | +585.36% | 4 | May 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $53 → $47 | $56.09 | -16.21% | 4 | May 8, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $15 → $13 | $9.16 | +41.92% | 3 | May 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $124 → $104 | $58.14 | +78.88% | 1 | May 5, 2025 | |
| SMMT Summit Therapeutics | Maintains: Buy | $37 → $41 | $27.07 | +51.46% | 2 | May 2, 2025 | |
| FOLD Amicus Therapeutics | Maintains: Neutral | $12 → $9 | $6.32 | +42.52% | 2 | May 2, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Buy | $9 → $10 | $10.33 | -3.19% | 11 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $917 → $804 | $558.87 | +43.86% | 11 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $219 → $197 | $131.95 | +49.30% | 4 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $32 | $22.95 | +39.43% | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $3.36 | +435.71% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $96 | $113.18 | -15.18% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $99 → $51 | $27.61 | +84.75% | 10 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $40 | $13.44 | +197.62% | 5 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $12 | $11.49 | +4.44% | 8 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $20 | $13.70 | +46.04% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $63 → $70 | $75.59 | -7.40% | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $198 → $370 | $401.80 | -7.91% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $76 | $28.44 | +167.23% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $33 → $37 | $43.03 | -14.01% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $53 | $35.05 | +51.21% | 9 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $313 → $350 | $296.88 | +17.89% | 7 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $442 → $559 | $462.13 | +20.96% | 4 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $5 | $16.92 | -70.45% | 5 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $31 | $1.08 | +2,770.37% | 7 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $257 → $225 | $297.02 | -24.25% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $22 | $4.04 | +444.55% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.15 | - | 4 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $30 | $4.68 | +541.03% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $5.68 | +58.45% | 6 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $3 | $2.63 | +14.07% | 4 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $15 → $12 | $23.53 | -49.00% | 8 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $3.91 | +53.45% | 3 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $39 → $43 | $57.56 | -25.30% | 1 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $3 → $2 | $2.95 | -32.20% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $125 → $100 | $11.55 | +765.80% | 1 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $560 → $600 | $5.74 | +10,352.96% | 3 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $57 → $50 | $96.48 | -48.18% | 4 | Mar 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $15.93 | +182.49% | 1 | Mar 17, 2020 |
Sarepta Therapeutics
Jun 17, 2025
Downgrades: Neutral
Price Target: $29
Current: $15.91
Upside: +82.28%
Enliven Therapeutics
Jun 16, 2025
Initiates: Buy
Price Target: $37
Current: $18.86
Upside: +96.18%
4D Molecular Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $51 → $44
Current: $6.42
Upside: +585.36%
CRISPR Therapeutics AG
May 8, 2025
Maintains: Neutral
Price Target: $53 → $47
Current: $56.09
Upside: -16.21%
Arcus Biosciences
May 8, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $9.16
Upside: +41.92%
BioMarin Pharmaceutical
May 5, 2025
Maintains: Buy
Price Target: $124 → $104
Current: $58.14
Upside: +78.88%
Summit Therapeutics
May 2, 2025
Maintains: Buy
Price Target: $37 → $41
Current: $27.07
Upside: +51.46%
Amicus Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $6.32
Upside: +42.52%
Adaptive Biotechnologies
May 2, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $10.33
Upside: -3.19%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Buy
Price Target: $917 → $804
Current: $558.87
Upside: +43.86%
Apr 23, 2025
Maintains: Buy
Price Target: $219 → $197
Current: $131.95
Upside: +49.30%
Mar 3, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $22.95
Upside: +39.43%
Feb 27, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $3.36
Upside: +435.71%
Feb 12, 2025
Maintains: Neutral
Price Target: $85 → $96
Current: $113.18
Upside: -15.18%
Jan 29, 2025
Downgrades: Neutral
Price Target: $99 → $51
Current: $27.61
Upside: +84.75%
Jan 28, 2025
Maintains: Buy
Price Target: $45 → $40
Current: $13.44
Upside: +197.62%
Jan 14, 2025
Maintains: Neutral
Price Target: $20 → $12
Current: $11.49
Upside: +4.44%
Dec 12, 2024
Maintains: Neutral
Price Target: $9 → $20
Current: $13.70
Upside: +46.04%
Oct 30, 2024
Maintains: Neutral
Price Target: $63 → $70
Current: $75.59
Upside: -7.40%
Aug 16, 2024
Upgrades: Buy
Price Target: $198 → $370
Current: $401.80
Upside: -7.91%
Aug 2, 2024
Maintains: Buy
Price Target: $67 → $76
Current: $28.44
Upside: +167.23%
Aug 2, 2024
Maintains: Sell
Price Target: $33 → $37
Current: $43.03
Upside: -14.01%
Jun 4, 2024
Maintains: Neutral
Price Target: $33 → $53
Current: $35.05
Upside: +51.21%
Feb 8, 2024
Maintains: Buy
Price Target: $313 → $350
Current: $296.88
Upside: +17.89%
Jan 31, 2024
Maintains: Buy
Price Target: $442 → $559
Current: $462.13
Upside: +20.96%
Aug 15, 2023
Maintains: Neutral
Price Target: $4.5 → $5
Current: $16.92
Upside: -70.45%
Mar 2, 2023
Maintains: Buy
Price Target: $35 → $31
Current: $1.08
Upside: +2,770.37%
Feb 24, 2023
Maintains: Overweight
Price Target: $257 → $225
Current: $297.02
Upside: -24.25%
Nov 14, 2022
Initiates: Neutral
Price Target: $22
Current: $4.04
Upside: +444.55%
Nov 11, 2022
Downgrades: Neutral
Price Target: n/a
Current: $11.15
Upside: -
Nov 10, 2022
Maintains: Neutral
Price Target: $60 → $30
Current: $4.68
Upside: +541.03%
Nov 9, 2022
Maintains: Neutral
Price Target: $8 → $9
Current: $5.68
Upside: +58.45%
Nov 9, 2022
Downgrades: Neutral
Price Target: $16 → $3
Current: $2.63
Upside: +14.07%
Nov 4, 2022
Downgrades: Sell
Price Target: $15 → $12
Current: $23.53
Upside: -49.00%
Nov 3, 2022
Maintains: Neutral
Price Target: $7 → $6
Current: $3.91
Upside: +53.45%
Oct 28, 2022
Maintains: Neutral
Price Target: $39 → $43
Current: $57.56
Upside: -25.30%
May 24, 2022
Maintains: Sell
Price Target: $3 → $2
Current: $2.95
Upside: -32.20%
May 24, 2022
Maintains: Sell
Price Target: $125 → $100
Current: $11.55
Upside: +765.80%
Mar 4, 2021
Upgrades: Buy
Price Target: $560 → $600
Current: $5.74
Upside: +10,352.96%
Mar 19, 2020
Maintains: Neutral
Price Target: $57 → $50
Current: $96.48
Upside: -48.18%
Mar 17, 2020
Initiates: Neutral
Price Target: $45
Current: $15.93
Upside: +182.49%